Kynexis pockets €97m to advance cognition-focused schizophrenia drug

Kynexis pockets €97m to advance cognition-focused schizophrenia drug is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Annabel Kartal Allen · 2026-08-20

Kynexis will now prepare for registrational studies on lead asset, KYN-5356 in cognitive impairment associated with schizophrenia (CIAS).

Source: Pharmaceutical Technology